

Adelaide Today  16 ° / 26 ° >

The Advertiser
We're for you

 Hi, George ▾

Business Stockhead

The dementia challenge: Which ASX



 [My News](#)  [Today's Paper](#) [SA](#) [World](#) [Sport](#) [Business](#) [Opinion](#) [Education](#) [Health](#) [Lifestyle](#) [Entertainment](#) [Puzzles](#) 



The search for a dementia breakthrough is gathering pace in Australia and around the world. Pic: Getty Images

Dementia is the leading cause of death in Australia while ranking among major causes of disability and dependency in older people



dependency among older people.
Stockhead

Everything you need to know before the ASX opens
In Australia, [dementia is the leading cause of death](#), while globally it ranks among the major causes of disability and dependency in older people. And, getting things right, everything took back for the ASX 500 to open its doors and begins trading today.

That research effort includes Australia, which is marking Dementia Action Week. To coincide with the week, seven Australian startups were announced as recipients of a combined \$15.6 million in funding to accelerate the



developing new therapies capable of slowing or changing its progression.

Stockhead

The gold rush of schizophrenia drugs reflected in the global Alzheimer's drug development pipeline, with 192 clinical trials testing 158 drugs in 2026 according to an annual report led by Alzheimer's researcher Dr Jeffrey Cummings.

For ASX investors, the opportunity extends from cognitive assessments in Alzheimer's trials to potential treatments and therapies targeting the shared



focused on tackling the disease.

Leaders & Companies



SA Business



Business

Blood spilt as chair, directors ousted at iconic Aussie company

Mayfair Hotel to be transformed after \$75m sale

Digital air traffic control towers not fit for WFH, says Airservices boss

Cogstate at forefront of Alzheimer's clinical trials

work to develop potential treatments for Alzheimer's disease, which is the most common cause of dementia, including US-based Eli Lilly and Japanese



(brand name Kisunla).

SA News



Tasmania



SA News

Adelaide Hills wedding venue folds leaving couples scrambling

'Never being seen': Hospital wait hits 2077 days

Former Crow sacked for inappropriate conduct

Donanemab is a monoclonal antibody administered by intravenous (IV) infusion and designed to target and remove amyloid plaques from the brain.

The phase III trial assessed whether removing the plaques could slow cognitive and functional decline in people with early Alzheimer's disease.

Trending now

Read More

Eisai is the developer of lecanemab (Leqembi), another disease-modifying Alzheimer's treatment which myloid in the brain, and was only person Dolly Parton wanted by deathbed



CGS manages cognitive endpoints on behalf of pharmaceutical companies, using a combination of technology and human services to ensure the quality of data collected at clinical trial sites for Alzheimer's and other neurodegenerative diseases. 'Ultimate sycophant': Harry hails Aussie social media ban, warns of AI threat

O'Connor said.

"Unacceptable": PM lashes OpenAI Medicare hack, three more sites being collected.



pharmaceutical companies, all of the 'What?': Australian council's 39k fines rakes in \$8m



He said that work includes:

Just Adelaide things: Stobie pole snapped in bizarre crash. Training staff at clinical sites (research hospitals)



Puzzles

Boy George gained fame in the 1980s as the lead singer of what band?



• Monitoring (auditing) of that data to ensure quality

• Delivery of telehealth-style assessments by Cogstate's 400-plus consulting neuropsychologists

Algorithmic and human monitoring of data



Shock lives of 40yo

Hanson brothers now



O'Connor said all these services and technology were designed to potential errors in the data.

CGS is now managing cognitive endpoints and ensuring data quality for both Lilly and Eisai as they investigate whether their approved early Alzheimer's treatments can be used even earlier.

O'Connor said the companies were moving into treating "pre-symptomatic" or "pre-clinical" Alzheimer's disease, where people may have amyloid plaques in their brains but do not yet have the memory impairment associated with dementia.

"It's sort of akin to treating cholesterol to prevent heart disease," O'Connor said, referring to the prospect of treating amyloid accumulation before significant cognitive symptoms develop.

"These plaques can occur up to 20 years before symptoms arrive.

"The hypothesis is that if removed through treatment before symptoms, can the symptoms be stopped from ever occurring."

Stockhead

He said the shift toward treating Alzheimer's earlier was also being enabled by advances in blood-based biomarkers.

In July 2026, Australia's Therapeutic Goods Administration (TGA) approved a blood test that can help identify amyloid pathology associated with Alzheimer's disease.

Roche's Elecsys Phospho-Tau (217P) Plasma (pTau217) test was developed in collaboration with Eli Lilly and was also cleared in August by the FDA.

"Eli Lilly's and Eisai's phase III trials are expected to conclude in 2027 and if they work Alzheimer's has changed forever because we now start treating people at the pre-symptomatic stage," O'Connor said.

CGS also has a Cognigram Digital Cognitive Assessment System, used by physicians to measure cognitive function and detect changes over time.

It assesses areas including processing speed, attention, visual learning, working memory, visual motor function and executive function.

The test can be used to assess cognition at a single point in time or track cognitive change through periodic assessments.

"There is a potential future where a simple blood test can identify the formation of plaques in the brain," O'Connor said.

"Cogstate digital assessments can then identify any functional impairment which will provide insight into the potential rate of decline.

"Then, through drugs approved for use in this earlier stage of disease, we can remove plaques before the horrendous memory impairment takes hold. It is super exciting."

Countdown to Actinogen's phase III Alzheimer's trial readout

[Actinogen Medical \(ASX:ACW\)](#) is the only ASX-listed healthcare company with an advanced program focused on Alzheimer's disease.

ACW's lead candidate Xanamem is in a phase 2b/3 trial dubbed XanaMIA, with topline results expected in November.

Xanamem is described by the company as the "first and only potent oral inhibitor of 11 β -HSD1", an enzyme involved in regulating cortisol in brain regions linked to memory and mood.

The oral drug candidate is designed to reduce excess cortisol production in the brain while preserving normal cortisol levels elsewhere in the body, with the aim of slowing cognitive decline.

"As national conversations around brain health take centre stage for Dementia Action Week, our team is staying sharply focused on our November trial readout," ACW chief financial officer Will Souter told Stockhead.

"We are rapidly approaching a pivotal moment that we hope will deliver a meaningful new treatment option for patients and their families."

"Dementia Action Week is a timely reminder of why we do what we do every day at Actinogen.

With trial sites fully enrolled and our upcoming November results on track, we are working hard to advance Xanamem toward becoming a potential breakthrough in Alzheimer's care."

Alterity eyes broader dementia potential for lead drug

[Alterity Therapeutics \(ASX:ATH\)](#) is developing its lead asset ATH434 for multiple system atrophy (MSA), a rare and aggressive Parkinsonian disorder.

The neurodegenerative disease, which affects up to 50,000 patients in the US, is characterised by the build-up of excess iron and aggregation of a protein called alpha-synuclein in the central nervous system (CNS).

ATH said the underlying biology is relevant across a broader group of neurodegenerative diseases.

Alpha-synuclein is a shared hallmark of MSA, Parkinson's disease, and dementia with Lewy bodies, one of the most common forms of dementia after Alzheimer's disease. Alzheimer's itself is driven by different proteins, amyloid-beta and tau.

The company describes ATH434 as an "iron chaperone", an orally administered small molecule designed to redistribute excess reactive iron within brain cells.

"ATH434 targets excess reactive iron in the brain, a key driver of alpha-synuclein misfolding," CEO Dr David Stamler told Stockhead.

"Right now our focus is on Multiple System Atrophy, a rapidly progressing disease with no approved therapy.

"The alpha-synuclein protein misfolds in a number of other neurodegenerative diseases, including dementia with Lewy bodies and in Parkinson's disease, where many patients develop dementia."

In preclinical models of MSA and Parkinson's disease, ATH434 reduced alpha-synuclein aggregation, preserved neurons, and improved motor function.

ATH is preparing for a phase III trial of ATH434 in MSA after reaching agreement with the US Food and Drug Administration (FDA) at an End-of-Phase 2 meeting on key elements of the study design, including the dose and primary endpoint. ATH434 has FDA Fast Track designation and orphan drug designation in the US and EU.

While MSA is ATH's immediate focus, the company sees potential for ATH434 to be explored in other neurodegenerative diseases, including dementia with Lewy Bodies.

"The biology we are targeting is shared across these conditions, which is why the mechanism is relevant well beyond MSA," Stamler said.

The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.

Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.

At Stockhead, we tell it like it is. While Alterity Therapeutics is a Stockhead advertiser, the company did not sponsor this article.

Originally published as [The dementia challenge: Which ASX stocks are chasing a breakthrough?](#)

Membership	About Us	Contact Us	Our News Network	Our Partners	Our Apps
Subscription packages	About us	Help and support	Herald Sun	Buy Search Sell Classifieds	 
Group/Corporate subscriptions	Meet the team	FAQs	Courier Mail	Find Your Local	
The Advertiser app	Job opportunities	Standards of practice	The Daily Telegraph	Foxsports	
Today's Paper	Code of conduct	Letter to the Editor	news.com.au	Foxtel	
Newsletters	Subscription FAQs	Licensing & Reprints	The Australian	Hipages	
	Subscription terms	Advertise with us	The Mercury	Kayo	
	Financial Hardship Policy		Geelong Advertiser	My Tributes	
			The Cairns Post	Punters	
			Gold Coast Bulletin	odds.com.au	
			Townsville Bulletin	racenet.com.au	
			The Chronicle	realestate.com.au	
			NT News	News24 Australia	
			The Weekly Times	Coupons	
			CODE Sports		

A NOTE ABOUT RELEVANT CONTENT: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out of targeted advertising based on your browsing behaviour on our network. Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

Nationwide News Pty Ltd © 2026. All times ACST (GMT +09:30). Powered by WordPress.com VIP

[Privacy policy](#) [Relevant ads opt-out](#) [Cookie policy](#) [Terms of use](#)